LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Potential Biomarker Found for Sudden Infant Death Syndrome

By LabMedica International staff writers
Posted on 23 May 2022
Print article
Image: The DetectX Butyrylcholinesterase (BChE) Fluorescent Activity Kit measures BChE activity in a wide variety of samples, utilizing a proprietary non-fluorescent molecule, ThioStar, which fluoresces when bound to the thiol reaction product of BChE and its substrate (Photo courtesy of Arbor Assays)
Image: The DetectX Butyrylcholinesterase (BChE) Fluorescent Activity Kit measures BChE activity in a wide variety of samples, utilizing a proprietary non-fluorescent molecule, ThioStar, which fluoresces when bound to the thiol reaction product of BChE and its substrate (Photo courtesy of Arbor Assays)

The term Sudden Unexpected Death in Infancy (SUDI) covers both explained and unexplained deaths. The unexplained deaths are termed Sudden Infant Death Syndrome (SIDS). Despite intensive studies over the past decades, the mechanisms which lead to SIDS remain elusive.

It is currently believed that SIDS is not due to a single factor, but is multi-factorial in origin. Acetylcholine (ACh) is a major neurotransmitter of the autonomic nervous system and the principal neurotransmitter of the parasympathetic nervous system. It is hydrolyzed at cholinergic synapses by two enzymes, Acetylcholinesterase (AChE), and Butyrlycholinesterase (BChE) (also known as pseudocholinesterase).

Clinical Scientists at the Children's Hospital at Westmead (Westmead, Australia) analyzed 722 dried blood samples (DBS) including 67 DBS (58% male) from SUDI infants (26 SIDS and 41 Non-SIDS), and 655 date of birth- and gender-matched controls: SIDS cases, mean age-at death 15.7 (± 8·1) weeks, (4-35 weeks), 54% male and Non-SIDS cases, mean age at death 31.7 (± 30) weeks, (1-103 weeks), 64% male.

Total BChE for each sample was quantified using the DetectX Butyrylcholinesterase Fluorescent Activity Kit (Arbor Assays, Ann Arbor, MI, USA) and the signal was read at 510nm with excitation at 390nm. Total protein in each sample was quantified using the BCA (Bicinchoninic acid) Dual Range Protein Detection Kit (Arbor Assays). The specific activity of BChE (BChEsa) was calculated by dividing BChE activity (mU/mL) by the total protein content (µg/ml) giving BChEsa in mU/µg. Results were reported in U/mg.

The investigators reported that conditional logistic regression showed that in groups where cases were reported as “SIDS death” there was strong evidence that lower BChE specific activity (BChEsa) was associated with death (OR=0.73 per U/mg, 95% CI 0.60-0.89), whereas in groups with a “Non-SIDS death” as the case there was no evidence of a linear association between BChEsa and death (OR=1.001 per U/mg, 95% CI 0.89-1.13).

The authors concluded that BChEsa, measured in dried blood spots taken 2-3 days after birth, was lower in babies who subsequently died of SIDS compared to surviving controls and other Non-SIDS deaths. They concluded that a previously unidentified cholinergic deficit, identifiable by abnormal-BChEsa, is present at birth in SIDS babies and represents a measurable, specific vulnerability prior to their death. The study was published on May 06, 2022 in the journal EBioMedicine.

Related Links:
Children's Hospital at Westmead 
Arbor Assays 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.